Contacts, documents and full notice history are available with a subscription.
Solicitation NONE Expired 1 notice 3 documents

Office of Clinical Pharmacology / Division of Applied Regulatory Science (DARS) – Critical DARS Laboratory Supplies FDA-CDER-25-130555

Solicitation FDA-CDER-25-130555 Copied Notice ID f2263abf750a489983a26a48b50ad839 Copied HEALTH AND HUMAN SERVICES, DEPARTMENT OF — FDA OFFICE OF ACQ GRANT SVCS
SAM.gov
Posted
Sep 08, 2025
Deadline
Sep 12, 2025
Set-aside
NONE
NAICS
541714
PSC
AJ12

Summary

AI-generated · Sep 09, 2025

Provide cryopreserved female donor hepatocytes for a study on how female sex hormones affect in vitro drug metabolism and transport. Six donors are required: three aged 20–35 and three aged 50–70. Each donor lot must contain at least 5 million viable hepatocytes per vial, be platable in 12-well plates, and remain functional for 4–5 days after plating. Qualification must include metabolism capability for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and transporter capability for OATP1B1, OATP1B3 (OAT2 and OCT1 if available).

The supplier must provide thawing, plating, and culturing protocols, including media composition and sources, sent as PDF files before shipping the hepatocytes. Up to 72 vials of cryopreserved hepatocytes will be provided from 6 or 12 donors, depending on their demonstrated metabolism and transporter activity.

The Division of Applied Regulatory Science (DARS) OCP/OTS/CDER is conducting a research project to examine the effect of female sex hormones on in vitro drug metabolism and transport. As part of this process, DARS needs to acquire cryopreserved human hepatocytes from multiple female donors of different age groups to conduct this research. For successful metabolism and transporter function to occur the following quality characteristics are essential for the study: Single female donor lots Three donors aged 20-35 years and three donors aged 50-70 years A minimum of 5 106 (5 million) viable hepatocytes per vial Must be platable in 12-well plates and remain functional for 4-5 days post-plating Metabolism- and/or transporter-qualified Metabolism qualifications: CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 Transporter qualifications: OATP1B1, OATP1B3 (OAT2 and OCT1 if available) The supplier is to provide protocol(s) for the thawing, plating and culturing the hepatocytes. This is to include the media composition and source for all these stages for the hepatocytes. The protocol(s) are to be sent to Donna Volpe (donna.volpe@fda.hhs.gov) as .pdf files prior to shipping the hepatocyte vials. The supplier will provide up to a total of 72 vials of cryopreserved human hepatocytes from 6 or 12 different female donors, depending on how the hepatocytes are qualified/certified for metabolism and transporter activity.

From Solicitation posted on Sep 08, 2025

Notice history

1
  1. Solicitation LATEST Posted Sep 08, 2025

Details

Solicitation number FDA-CDER-25-130555
Notice ID f2263abf750a489983a26a48b50ad839
Notice type Solicitation
Product / Service (PSC) AJ12
NAICS 541714
Set-aside No Set aside used
Place of performance Silver Spring, Maryland
Archive date Sep 15, 2025

Award Information

Not yet awarded

Contacts

primary
Rodney D. Aytch

Email

Phone

Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF
FOOD AND DRUG ADMINISTRATION
FDA OFFICE OF ACQ GRANT SVCS

Place of Performance

Silver Spring, Maryland 20993
USA

Dates

Posted Sep 08, 2025 11 months ago
Last Updated Aug 06, 2026 2 days ago
Due Sep 12, 2025 10 months ago